Author

Vipin Arora 1

1 AbbVie

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH SIGNIFICANTLY IMPROVED INFLAMMATORY BOWEL DISEASE RELATED QUALITY OF LIFE IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Marla C. Dubinsky, Scott D. Lee, Remo Panaccione, Maria T. Abreu, Severine Vermeire, Trevor Lissoos, Nathan Morris, Vipin Arora, Mingyang Shan, April Naegeli, Bruce E. Sands

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND IMPROVED HEALTH-RELATED QUALITY OF LIFE AFTER 52-WEEKS OF MIRIKIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: AN UPDATE FROM A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

Marc Ferrante, William Sandborn, Bal R Bandhari, Geert D’Haens, Brian G. Feagan, Michael Durante, Vipin Arora, Jay Tuttle, April Naegeli

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Geert R. D'Haens, Maria T. Abreu, Ruth Belin, Elisa Gomez Valderas, Debra Miller, April Naegeli, Vipin Arora, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY

Geert R. D'Haens, Taku Kobayashi, Nathan Morris, Trevor Lissoos, Amy Hoover, Xingyuan Li, Vipin Arora, Catherine Milch, William J. Sandborn, Bruce E. Sands

EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 104-WEEK RESULTS FROM A PHASE 2 RANDOMISED CONTROLLED TRIAL

Isabel Redondo, Brian Feagan, Remo Panaccione, Christian Selinger, Trevor Lissoos, Vipin Arora, Milan Lukas, Katsuyoshi Matsuoka, Toshifumi Hibi

Histologic remission and mucosal healing in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis

Rish K. Pai, James Canavan, Jay Tuttle, Michael Durante, Vipin Arora, Catherine Milch, Noam Harpaz, Geert D’Haens, Bruce E. Sands, William Sandborn

Item 1 - 9 / 9
1